Ask the Experts: Progression and Resistance
laurabbook@gmail.com2021-01-21T14:27:05-08:00*January 2021* The first of three webinars on Progression and Resistance in EGFR+ lung cancer. This first webinar is on Histological
*January 2021* The first of three webinars on Progression and Resistance in EGFR+ lung cancer. This first webinar is on Histological
*December 2020* EGFR, ALK, and ROS1 abnormalities are no longer the only oncogenic drivers worthy of discussion in non–small cell lung cancer (NSCLC),
*December 2020* Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in
*December 2020* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable
*November 2020* Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, efficiently penetrates the blood-brain barrier. This study explored whether treatment with
*December 2020* Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline
*December 2020* John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson
*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung
*November 2020* Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon
*November 2020* In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK